Strata Critical Medical (NASDAQ:SRTA) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Strata Critical Medical (NASDAQ:SRTA) to a hold rating in a report published on Thursday,Zacks.com reports.

Several other brokerages have also issued reports on SRTA. Craig Hallum began coverage on shares of Strata Critical Medical in a report on Wednesday. They issued a “buy” rating and a $8.00 price target for the company. Weiss Ratings started coverage on Strata Critical Medical in a research note on Tuesday. They issued a “hold (c-)” rating for the company. Finally, B. Riley Financial started coverage on Strata Critical Medical in a research report on Wednesday. They set a “buy” rating and a $8.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Strata Critical Medical presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Strata Critical Medical Stock Down 2.6%

Shares of NASDAQ SRTA opened at $4.14 on Thursday. The company has a market cap of $357.57 million, a P/E ratio of 8.45 and a beta of 2.05. Strata Critical Medical has a 52-week low of $2.35 and a 52-week high of $6.02.

About Strata Critical Medical

Blade Air Mobility, Inc provides air transportation alternatives to the congested ground routes in the United States. It provides its services through charter and by-the-seat flights using helicopters, jets, turboprops, and amphibious seaplanes. The company was founded in 2014 and is headquartered in New York, New York.